2 active not recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Geneos Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012 - HCC | Phase 2 | Recruiting | Geneos Therapeutics | 90 | 2026-09-01 | 2026-09-23 |
| Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics, CELLECTRA®2000 EP Device supplied by Geneos Therapeutics, Plasmid encoded IL-12 - Glioblastoma | Phase 1 | Active not recruiting | Washington University School of Medicine | 9 | 2020-07-14 | 2026-05-07 |
| GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC GNOS-PV02, INO-9012, Pembrolizumab - HCC | Phase 1 / Phase 2 | Active not recruiting | Geneos Therapeutics | 36 | 2020-03-01 | 2026-09-24 |
Glioblastoma (1)
rocakinogene sifuplasmid (3) · Vaccines (1) · pembrolizumab (1)
United States (3) · New Zealand (2)
Tanner M Johanns, M.D., Ph.D. (1)
R01NS112712 (1)